---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-24-000069"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T16:46:10.589366+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edwards Q2 revenue +8% CC, TAVR guidance cut to 5-7%; announces $1.2B in acquisitions

## Summary
- Q2 continuing ops sales $1.35B (+7% reported, +8% CC); adj. EPS $0.70, GAAP EPS $0.61.
- TAVR sales $1.0B, growth 5% (6% CC); FY2024 TAVR guidance lowered to 5-7% from 8-10%.
- TMTT sales $83M, +75%; FY2024 TMTT guidance raised to high end of $320-340M range.
- Entered agreement to acquire JenaValve (aortic regurgitation) and exercised option to acquire Endotronix (PA pressure sensor); total upfront ~$1.2B cash plus up to $445M milestones.
- Critical Care sale ($4.2B) on track to close late Q3 2024; Q3 sales guidance $1.56-1.64B, EPS $0.67-0.71.

## SEC filing metadata
- accession: 0001099800-24-000069
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000069/0001099800-24-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000069/ew-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-24-000069
- JSON: https://secwatch.observer/filing/0001099800-24-000069.json
- Plain text: https://secwatch.observer/filing/0001099800-24-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.